These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 16617561

  • 1. Options and limits of surgery after pre-operative chemotherapy in breast cancer.
    Thomas A, Ohlinger R, Hauschild M, Mustea A, Blohmer JU, Kümmel S.
    Anticancer Res; 2006; 26(2C):1677-82. PubMed ID: 16617561
    [Abstract] [Full Text] [Related]

  • 2. Neoadjuvant chemotherapy in breast cancer.
    Charfare H, Limongelli S, Purushotham AD.
    Br J Surg; 2005 Jan; 92(1):14-23. PubMed ID: 15635596
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer.
    Shimizu C, Ando M, Kouno T, Katsumata N, Fujiwara Y.
    Jpn J Clin Oncol; 2007 Jan; 37(1):1-8. PubMed ID: 17202251
    [Abstract] [Full Text] [Related]

  • 6. The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer.
    Clouth B, Chandrasekharan S, Inwang R, Smith S, Davidson N, Sauven P.
    Eur J Surg Oncol; 2007 Oct; 33(8):961-6. PubMed ID: 17215100
    [Abstract] [Full Text] [Related]

  • 7. Preoperative (neoadjuvant) systemic treatment of breast cancer.
    Kaufmann M, von Minckwitz G, Rody A.
    Breast; 2005 Dec; 14(6):576-81. PubMed ID: 16199160
    [Abstract] [Full Text] [Related]

  • 8. [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].
    Straver ME, van Adrichem JC, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Gilhuijs KG, Oldenburg HS, Wesseling J, Russell NS, Antonini N, Vrancken Peeters MT.
    Ned Tijdschr Geneeskd; 2008 Nov 15; 152(46):2519-25. PubMed ID: 19055260
    [Abstract] [Full Text] [Related]

  • 9. [Does primary chemotherapy really increase the rate of breast conserving treatments?].
    Hennequin C, Espié M, Misset JL, Maylin C.
    Cancer Radiother; 2004 Feb 15; 8(1):48-53. PubMed ID: 15093201
    [Abstract] [Full Text] [Related]

  • 10. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 11. Axillary-conserving surgery is facilitated by neoadjuvant chemotherapy of breast cancer.
    Beatty JD, Precht LM, Lowe K, Atwood M.
    Am J Surg; 2009 May 12; 197(5):637-41; discussion 641-2. PubMed ID: 19321159
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Cho N, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    Breast Cancer Res Treat; 2009 Jul 12; 116(1):153-60. PubMed ID: 18787948
    [Abstract] [Full Text] [Related]

  • 14. Primary systemic therapy of breast cancer.
    Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH.
    Oncologist; 2006 Jun 12; 11(6):574-89. PubMed ID: 16794237
    [Abstract] [Full Text] [Related]

  • 15. [New combination chemotherapy regimens in the primary treatment of operable breast cancer].
    Conti F, Sergi D, Foggi P, Abbate MI, Lopez M.
    Clin Ter; 2007 Jun 12; 158(1):55-75. PubMed ID: 17405660
    [Abstract] [Full Text] [Related]

  • 16. Primary chemotherapy in operable breast cancer.
    Bonadonna G, Valagussa P.
    Semin Oncol; 1996 Aug 12; 23(4):464-74. PubMed ID: 8757273
    [Abstract] [Full Text] [Related]

  • 17. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
    Ardavanis A, Scorilas A, Tryfonopoulos D, Orphanos G, Missitzis I, Karamouzis M, Chrysochoou M, Sotiropoulou A, Arnogiannaki N, Ioannidis G, Pissakas G, Rigatos G.
    Oncologist; 2006 Jun 12; 11(6):563-73. PubMed ID: 16794236
    [Abstract] [Full Text] [Related]

  • 18. Surgical management of inflammatory breast cancer.
    Singletary SE.
    Semin Oncol; 2008 Feb 12; 35(1):72-7. PubMed ID: 18308148
    [Abstract] [Full Text] [Related]

  • 19. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A, Guray M, Hennessy BT, Middleton LP, Buchholz TA, Valero V, Sahin AA.
    Cancer; 2009 Apr 15; 115(8):1605-12. PubMed ID: 19197997
    [Abstract] [Full Text] [Related]

  • 20. Dose-dense primary chemotherapy, as part of multidisciplinary treatment, for inoperable stage III B breast cancer--long-term results of a phase II trial.
    Massidda B, Atzori F, Scanu A, Contu A, Farris A, Catino AM, Palmeri S, Minerba L, Ionta MT.
    Oncology; 2007 Apr 15; 72(1-2):17-26. PubMed ID: 17998786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.